Research News and Highlights

Explore news, updates and cutting-edge research related to real-world data and ALZ-NET.

Network news

Ralph H. Johnson Health Care System Becomes First Veterans Affairs Site to Join ALZ-NET

The Ralph H. Johnson Veterans Affairs Health Care System in Charleston, South Carolina, has become the first VA site to join ALZ-NET, marking a significant milestone in expanding Alzheimer's treatment and care for the estimated 500,000 U.S. Veterans living with the disease. The collaboration is managed through VA's Alzheimer's Disease and Related Dementias National Coordinating Center (ADRD NCC), which will serve as the hub for onboarding additional VA sites — including planned expansions to Pittsburgh, Albany, and beyond. By contributing real-world data on newly approved amyloid-targeting therapies in Veteran patients, this partnership aims to improve both current care and future treatment outcomes.

Announced: April 6, 2026

First ALZ-NET Data Readout Marks Milestone in Building Real-World Evidence for Alzheimer’s Treatment

At CTAD 2025, ALZ-NET shared its first real-world data readout, showing that treatment patterns and participant demographics closely resemble clinical trial populations and that most individuals are being treated in the early stages of disease. Early findings also indicate stable cognition and function during the first year of therapy and ARIA rates consistent with expectations, demonstrating the value of ALZ-NET in understanding how approved treatments perform in routine practice.

Date presented: December 3, 2025

Alzheimer’s Association Welcomes FDA Action Approving Leqembi Weekly Subcutaneous Maintenance Dosing

The FDA has approved weekly subcutaneous maintenance dosing of Leqembi® (lecanemab) for early Alzheimer’s disease, making it the first amyloid-clearing antibody available via autoinjector. Patients who have completed the initial 18-month course of IV infusions may now transition to self- or caregiver-administered weekly injections at home, an option that is expected to reduce treatment burden and support longer-term use.

Date Published: August 29, 2025
Publication: Alzheimer's Association

More ALZ-NET news and highlights

[AAN 2026] Real-World Registry Study Shows Alzheimer's Drug Safety Outcomes, April 24, 2026

Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer's Disease Therapies, March 26, 2026

[AD/PD 2026] Tailored dosing, real-world data emerge as key in Alzheimer’s treatment era, March 24, 2026

ALZ-NET International - Chile: María Carrillo: “Los avances científicos pueden surgir en cualquier país, no solo de Estados Unidos", January 14, 2026

Four Years After Conception, ALZ-NET Registry Is Growing, December 19, 2025

Lead the Future of Alzheimer's Imaging — Join ALZ-NET, October 2, 2025

Alzheimer’s Med Donanemab Continues to Deliver Benefit at 3 Years, August 21, 2025

Early Diagnosis and Treatment of Alzheimer’s Disease, August 14, 2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer's Disease Care Through AI-Driven Imaging, May 19, 2025

New ‘Real World’ Data on Lecanemab Side Effects for Alzheimer’s, May 16, 2025

More and more older Americans want to know their Alzheimer's status, survey finds, April 29, 2025

American College of Radiology (ACR) and icometrix collaborate to improve the quality of care for people with Alzheimer’s disease, April 2, 2025

New Guidance for Gold-Standard Imaging Tests Assists Clinicians in Diagnosis and Management of Alzheimer’s and Other Dementia, January 8, 2025

New Clinical Practice Guideline on the Process for Diagnosing Alzheimer’s Disease or a Related Form of Cognitive Impairment or Dementia, December 23, 2024

ALZ-NET and Eisai Inc. to Collect Real-World Data to Support Postmarketing Requirements for LEQEMBI ® (lecanemab-irmb), October 3, 2024

Two New Deaths on Leqembi Highlight Need to Better Manage ARIA, August 16, 2024

FDA Approves New-Generation Acetylcholinesterase Inhibitor ALPHA-1062 for Mild-to-Moderate Alzheimer Disease, July 29, 2024

FDA approves treatment for adults with Alzheimer’s disease, July 2, 2024

Alzheimer’s Association Workgroup Publishes Biology-Based Criteria for Diagnosis and Staging of Alzheimer’s Disease, June 27, 2024

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (AD), January 31, 2024

Radiology Takes on Alzheimer's Disease, October 4, 2023

Isaac Health joins ALZ-NET as a participating telehealth site, September 6, 2023

FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval (lecanemab), July 6, 2023

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease (brexpiprazole), May 11, 2023

Emerging Therapies for Early Alzheimer’s Disease, April 3, 2023

Experts reframe ‘clinical meaningfulness’ in Alzheimer’s, February 7, 2023

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment (lecanemab), January 6, 2023

Alzheimer’s Association Launches ALZ-NET Registry for Study of New Treatments for Alzheimer's Disease in Real-World Setting, August 2, 2022

Alzheimer’s Association Launches ALZ-NET: A Long-Term Data Collection and Sharing Network for New Treatments, August 1, 2022

Working Towards a World Without Alzheimer’s and All Other Dementia, November 26, 2021

Alzheimer’s Association announces national data registry for quick, transparent data sharing, November 12, 2021

National Alzheimer Disease Registry Announced to Collect Clinical Practice Data, November 12, 2021

Publications from ALZ-NET

ALZ-NET: Using Real World Evidence to Inform the Future of Alzheimer’s Treatment and Care
Published: December 2022

Alzheimer’s Association launches ALZ-NET: A long-term data collection and sharing network for new treatment
Published: September 2022